Quarterly report [Sections 13 or 15(d)]

Schedule of Segment Information (Details)

v3.26.3
Schedule of Segment Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Change in fair value of Greenshoe Rights liability $ (11,413,000) $ (11,413,000)
Other expense (income) 24,000 (11,681,000) 15,000 15,819,000
Net loss (income) 3,531,000 (8,299,000) 10,882,000 22,646,000
Clinical Stage Biopharmaceutical Member]        
Segment Reporting [Line Items]        
Research and development 1,710,000 634,000 3,178,000 2,096,000
Salaries 353,000 373,000 1,124,000 1,006,000
Insurance 40,000 54,000 124,000 175,000
Stock-based compensation 46,000 379,000 138,000 386,000
Operating expenses 1,358,000 1,942,000 6,303,000 3,164,000
Loss on initial recognition of Greenshoe Rights liability 28,736,000
Change in fair value of Greenshoe Rights liability (11,413,000) (11,413,000)
Other expense (income) 24,000 (268,000) 15,000 (1,504,000)
Net loss (income) $ 3,531,000 $ (8,299,000) $ 10,882,000 $ 22,646,000